Inpharma Weekly

, Volume 1553, Issue 1, pp 15–15 | Cite as

Topotecan + paclitaxel: promising response, tolerability in advanced NSCLC

Clinical study


Lung Cancer Survival Rate Paclitaxel Partial Response Multicentre Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 2006

Personalised recommendations